1989
DOI: 10.1016/0092-8674(89)90844-1
|View full text |Cite
|
Sign up to set email alerts
|

Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

7
141
0

Year Published

1997
1997
2018
2018

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 286 publications
(148 citation statements)
references
References 39 publications
7
141
0
Order By: Relevance
“…The two genes were designated SUNI and SUN2 (suppressor of ninl-1). SUN2 is an essential gene and is a homologue of DoxA2 of Drosophila melanogaster (Pentz and Wright, 1991; Kawamura et al, 1996), a mouse transplantation antigen gene, P91A, (Lurquin et al, 1989), and the p58 gene encoding a component of the human 26S proteasome (DeMartino et al, 1994 and present study). In contrast, the SUN1 gene with an insertion at the mid-point of its open reading frame (ORF) does not confer a growth defect on the cells.…”
Section: Introductionmentioning
confidence: 99%
“…The two genes were designated SUNI and SUN2 (suppressor of ninl-1). SUN2 is an essential gene and is a homologue of DoxA2 of Drosophila melanogaster (Pentz and Wright, 1991; Kawamura et al, 1996), a mouse transplantation antigen gene, P91A, (Lurquin et al, 1989), and the p58 gene encoding a component of the human 26S proteasome (DeMartino et al, 1994 and present study). In contrast, the SUN1 gene with an insertion at the mid-point of its open reading frame (ORF) does not confer a growth defect on the cells.…”
Section: Introductionmentioning
confidence: 99%
“…The mechanism for this is unknown, although assessment of one of these regrowth tumors demonstrated a loss of the gene coding for the model antigen, a phenomenon that has been previously noted in antigen-loss tumor variants in human melanoma and murine P815 and SV40-transformed tumor models. [27][28][29][30] It is tempting to speculate that a vigorous antigen-specific antitumor CTL response in vivo might facilitate the generation of antigen-loss variants by eradicating tumor cells expressing the tumor antigen, permitting small numbers of tumor cells not expressing the targeted antigen to regrow. This observation supports the critical importance of T cell selective pressure against tumor progression and has important implications for the …”
Section: Discussionmentioning
confidence: 99%
“…These peptides became very real when they were first eluted from target cells by the group of H. G. Rammensee [65]. Peptides were also soon shown to be involved in anti-tumour CTL responses by T. Boon's group [66]. All became convincingly clear in the classical studies of P. Björkman, J. Strominger and D. Wiley in 1987, when the X-ray cristallography of a class I HLA-molecule revealed the peptide binding cleft [67,68].…”
Section: Further Analysismentioning
confidence: 99%